START FREE TRIAL

This Telehealth Stock Rally By RFK Jr. Looks Like Policy; It’s Actually A Margin SHIFT

Hims & Hers Health (NYSE:HIMS) did not report a surprise quarter, launch a blockbuster product, or raise guidance when...

Eli Lilly’s Foundayo & The GLP-1 Pivot From Innovation to Access Control!

Most coverage of Eli Lilly’s(NYSE:LLY) Foundayo launch has treated it like the next round in the company’s fight with...

The “Boring” Healthcare Stock Making A $5 Billion POWER MOVE!

The market loves excitement. But money is often made in boredom. That is what makes Gilead Sciences (NASDAQ:GILD) such...

This Biotech Stock Already Has A Blockbuster; So Why Is It ACQUIRING Another Rare Disease Asset?

There are biotech stories that look obvious, and then there are biotech stories that quietly change shape right in...

This “Broken” Biotech Just Forced Wall Street To Blink

Apellis Pharmaceuticals (NASDAQ:APLS) did not suddenly discover a miracle on Tuesday. What changed was the price investors were willing...

This Medical Device Stock Just Got CRUSHED On One Hidden Number; Did Wall Street Misread It?

Boston Scientific (NYSE:BSX) spent the weekend putting forward what looked, at first glance, like a clinically solid case for...

A First-In-Class Biotech Is Still Trading Below Its Strategic Value Today

A mid-cap biotech with the first approved therapy in a large, long-underfunded liver disease category is not supposed to...

Is Align A Classic Activist Win, Or A HARDER Consumer Story?

Align Technology (NASDAQ:ALGN) has become a useful test case for a very modern market question. What happens when Wall...

Agilent’s $950M Biocare Acquisition Could Unlock A Powerful Recurring Revenue Flywheel

The diagnostics and life sciences equipment industry rarely stands still. But recent developments around Agilent Technologies (NYSE:A) have drawn...

Qiagen Just Dropped Two Magic Words—And Wall Street Heard “Buyout”

Qiagen (NYSE:QGEN) just did the thing companies do right before Wall Street starts whispering louder. On March 2, CEO...

Is Merck’s HIV Win Really About Keytruda?

When Merck & Co. (NYSE:MRK) reported Phase 3 data showing its two-drug HIV regimen of doravirine and islatravir matched...

Did Novo Nordisk’s Trial Miss Just Hand Lilly The Edge?

It has been a bruising few weeks for Novo Nordisk (NYSE:NVO). First came the clinical disappointment: CagriSema, the company’s...